Document is current
Any future updates will be listed below
-
Authors
LaFleur, Martin W. https://orcid.org/0000-0002-5017-774X
Milling, Lauren E. https://orcid.org/0009-0002-4604-9435
Prathima, Priyamvada
Li, Vivian
Lemmen, Ashlyn M.
Streeter, Ivy S. L. https://orcid.org/0000-0003-0729-1042
Heisig, Paul K. S.
Derosia, Nicole M.
Riffo, Elizabeth
Xu, Haonan
Nguyen, Thao H. https://orcid.org/0000-0002-2767-0528
Kolengaden, Aashiya
Markson, Samuel C. https://orcid.org/0000-0001-9053-9867
Doench, John G. https://orcid.org/0000-0002-3707-9889
Sharpe, Arlene H. https://orcid.org/0000-0002-9736-2109
- License Information
-
More Information
Article History
Received: 23 April 2024
Accepted: 18 June 2025
First Online: 12 August 2025
Change Date: 14 August 2025
Change Type: Update
Change Details: Since the version of the article initially published, Source Data Fig. has been amended to correct “Control-g1 (1/10)” and “Stub1-g1 (3/10)” to “Control-g1 (2/10)” and “Stub1-g1 (2/10)” for the Fig. data. The updated is now available online.
Competing interests
: A.H.S. has patents or is pending royalties on the PD-1 pathway from Roche and Novartis. M.W.L., L.E.M., I.S.L.S., A.M.L., P.K.S.H., N.M.D. and A.H.S. have a patent on methods for modulating STUB1 for the treatment of cancer. A.H.S. is on the advisory boards for Elpiscience, Monopteros, Corner Therapeutics, Bioentre, Alixia, GlaxoSmithKline, Janssen, Amgen, AltruBio, ImmVue and MabQuest, and receives research funding from Calico Life Sciences LLC and Taiwan Bio. J.G.D. consults for Microsoft Research, Abata Therapeutics, Servier, Maze Therapeutics, BioNTech, Sangamo and Pfizer, consults for and has equity in Tango Therapeutics, serves as a paid scientific advisor to the Laboratory for Genomics Research, is funded in part by GlaxoSmithKline and receives funding support from the Functional Genomics Consortium: AbbVie, Bristol Myers Squibb, Janssen and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. His interests were reviewed and are managed by the Broad Institute in accordance with its conflict-of-interest policies. The other authors declare no competing interests.
